The Prognostic and Drug-targeting Value of Lymphoid Enhancer-binding Factor-1 in Hepatocellular Carcinoma

作者：Ruixiang Guo, Huiru Dai, Fuweijian Liu, Minling Liu, Xueying Li, Tingwei Li, Jiehao Liao, Zhe‐Sheng Chen, Yuchen Liu, Shuo Fang · 发表于：Recent Patents on Anti-Cancer Drug Discovery · 年份：2022 · DOI：10.2174/1574892817666220831122226 · 被引用次数：3 · 研究领域：Ferroptosis and cancer prognosis、Clusterin in disease pathology、Lymphatic System and Diseases

BACKGROUND: Lymphoid Enhancer-Binding Factor-1 (LEF1) was previously reported to contribute to a variety of malignancies, including Hepatocellular Carcinoma (HCC). However, its role in HCC is poorly understood. OBJECTIVES: To explore the role of LEF1 in HCC, including its prognostic and drug-targeting value. METHODS: The LEF1 expression and patient characteristics were investigated. The associations between clinical characteristics and LEF1 were analyzed using both univariate and multivariate logistic regression. Cox regression and Kaplan-Meier curves were used to explore the clinicopathological factors related to overall survival in patients with HCC. A nomogram to predict the survival rate was constructed and validated. The Kyoto Encyclopedia of Genes and Genomes database (KEGG) was used to explore the function of LEF1. Gene Set Enrichment Analysis (GSEA) was also performed using The Cancer Genome Atlas dataset. Furthermore, compounds that may have the potential to be targeted drugs in the treatment of LEF1-overexpressing HCC were identified using the Comparative Toxicogenomics Database (CTD), patents about these drugs in HCC were also reviewed through Worldwide Espacenet® and Patentscope®. RESULTS: Increased expression of LEF1 was significantly associated with high histological grade of HCC (odds ratio (OR) = 2.521 for grade (G) 2 vs. G1, OR = 2.550 for G3 vs. G1, OR = 7.081 for G4 vs. G1, all P < 0.05). A Kaplan-Meier survival curve showed that HCC patients with LEF1 over...